$QCOM: A leader in mobile chips, the company is accelerating its diversification into automotive, edge AI, data centers, and IoT. Q2 FY2026 results beat expectations (revenue of $10.6B, non-GAAP EPS of $2.65), with the automotive business hitting a record high, but mobile memory supply issues weighed on Q3 guidance. Current share price ≈ $202.96 (6/11 close 6.15%), market cap ≈ $214B Q2 FY2026 Earnings Report (released 4/29): Revenue $10.6B (slightly above expectations, slight YoY decline); Non-GAAP EPS $2.65 (beat); QCT (chips) $9.1B, QTL (licensing) $1.4B. Annualized automotive revenue exceeds $5B, with a target to surpass $6B by year-end; handheld devices impacted by memory shortages. Recent developments: Collaboration with SLB on edge AI power solutions; positive comments from Nvidia CEO Jensen Huang; Investor Day 2026 to be held on June 24, focusing on AI growth and diversification; rumors of custom chips for data centers for companies like ByteDance. No major negatives; next earnings report expected in late July. Key Rationale Strong performance in automotive and IoT (ADAS, digital chassis). Differentiated advantage in on-device AI (Snapdragon) to counter Nvidia/AMD’s data center expansion. Robust cash flow supports high dividends and share buybacks. Geopolitical/supply chain risks (Chinese market, memory) are short-term headwinds. Buy Zone: $195–$198 Solid fundamentals (Q2 beat accelerated diversification into automotive/AI), with stable dividends providing a buffer. Although the short-term mobile cycle and conservative guidance are weighing on valuations, the June 24 Investor Day is a key catalyst. #NVDA #AIStocks #QCOM #SPX #Tesla #Tariffs #Meta

$B*** volatility soars 10%-50%, insiders know the inside scoop. Full strategy? Outsiders needn't bother—exclusive to our group members. Hurry and click my profile to add me on WhatsApp #SP500 #Investing #StockInvesting #StockMarket #Stocks #QQQ #GAUZ #NVDA #US

$TMDX: A medical device company specializing in organ transplantation technology that uses its Organ Care System (OCS) platform to enable normothermic perfusion during organ transport, significantly improving transplant success rates. The company also operates the National OCS Program (NOP), which provides end-to-end logistics services and currently covers heart, lung, and liver transplants. Macro Context (3 Months): The organ shortage crisis is driving growth in transplant demand, while U.S. transplant modernization policies and the increase in DCD (donor after circulatory death) donors create a favorable environment for advanced preservation technologies like OCS. The company benefits from high regulatory barriers in the medical device sector and the potential for orphan drug/breakthrough device designations, with the NOP model shifting toward service revenue to drive high-margin growth. Key Catalysts: Accelerated patient recruitment for the ENHANCE Heart and DENOVO Lung trials (which have received full FDA approval); Q3-Q4 data updates or interim results will drive adoption for cardiac and pulmonary indications. European NOP launch (Italy H1 2026), with PAD Aviation investment strengthening the European logistics network. OCS Kidney program progress (preparing for clinical launch), with potential to contribute new revenue in late 2026/early 2027. Q2 earnings (around August) may demonstrate NOP volume growth and guidance confirmation/upward revision. The company’s core competitive advantage lies in the OCS platform’s technological barriers: patented ambient-temperature perfusion technology outperforms traditional cold preservation, reducing ischemic injury and expanding the donor pool (especially marginal donors), with clinical evidence supporting better transplant outcomes. Vertically integrated NOP model: Full-chain services from devices to logistics, already capturing a significant share of OCS transplants in the U.S.; reusable devices and service revenue create a high-stickiness moat. Execution and Expansion: Rapid commercialization (leading in liver transplants), progress in clinical trials, and international expansion (investment in European aviation), with $462 million in cash reserves to support growth investments. Regulatory and Data Advantages: Multiple FDA IDE approvals and ongoing registration trials pave the way for label expansion. Bullish Case: Strong demand clinical catalysts will drive volume growth in heart and lung transplants, moving beyond the current liver-dominated model. NOP international expansion provide visible multi-channel growth, with significant room for long-term penetration rate expansion. 12-Month Target: $118–$130 #TMDX #OrganTransplant #OCSPlatform #NOPGrowth #ENHANCEHeart #DENOVOLung #BiotechMedTech

$APPF: A leading SaaS company focused on real estate technology (PropTech), primarily providing property management companies with a cloud-based software platform that includes property management, leasing, maintenance, resident experience, and AI-driven value-added services. Its client base consists primarily of mid-sized property management firms, with a strong emphasis on AI innovation and unit growth. AppFolio is the leading SaaS provider in the property management vertical, benefiting from AI innovations (such as Leasing/Maintenance Performer), high retention rates, and recurring revenue driven by unit growth. The real estate market recovery and digital transformation provide long-term tailwinds, and the company enjoys high competitive barriers (network effects). Key Points (Current Stock Price and Recent Performance, as of the close on June 5, 2026) Closing Price: $166.94 ( 3.29 / 2.01%), Intraday Range: $161.85–$168.87. 52-week range: $142.73–$326.04; Market Cap ~$5.9B. YTD/1-year performance: Down approximately 22–28%, but rebounded following Q1 earnings. Q1 2026 Earnings (Announced April 23): Revenue: $262M ( 20% YoY), beat expectations. EPS: $1.61 (beat the $1.47 consensus). Units under management: 9.5 million ( 8% YoY). Non-GAAP operating margin: 27.3% (strong expansion). Share buyback: 703,000 shares ($125M). Full-year guidance raised: Revenue $1.11B–$1.125B (midpoint growth ~17.5%), non-GAAP operating margin 26–28%. Key Focus Areas for Next Earnings Report: AI product adoption, sustainability of unit growth, margin trajectory. Signs of a real estate market recovery (rents, occupancy). Macro: Interest rates, changes in housing supply. Short-term (1–3 months) target: $190–$210 #NVDA #TSLA #AAPL #MSFT #AMZN #GOOGL #META

$B*** volatility soars 10%-50%, insiders know the inside scoop. Full strategy? Outsiders needn't bother—exclusive to our group members. Hurry and click my profile to add me on WhatsApp #SP500 #Investing #StockInvesting #StockMarket #Stocks #QQQ #GAUZ #NVDA #US